6 unknown. 6 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Unknown 6 |
| Phase 3 | 2 | Unknown 2 |
Follow Hyperuricemia: new trials by email Literature Review of Hyperuricemia trials Research Report on Hyperuricemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia Febuxostat 20MG Tablets, Febuxostat 20MG Placebo, AR882 25MG - Primary Gout, Hyperuricemia | Phase 2 / Phase 3 | Unknown | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | 636 | 2024-04-22 | 2024-09-19 |
| Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia SHR4640 tablet, febuxostat tablet, SHR4640 placebo tablet - Primary Gout and Hyperuricemia | Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 129 | 2022-09-15 | 2022-08-24 |
| A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia SHR4640 dose1 plus Febuxostat dose1, SHR4640 dose1 plus Febuxostat dose2, SHR4640 dose2 plus Febuxostat dose3 - Hyperuricemia | Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 84 | 2019-12-03 | 2019-12-02 |
| Long-term Prednisone Use for End-stage Heart Failure prednisone - Heart Failure, Hyperuricemia | Phase 2 / Phase 3 | Unknown | Hebei Medical University | 90 | 2013-12-01 | 2017-01-12 |
| Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout levotofisopam - Hyperuricemia, Gout | Phase 2 | Unknown | Pharmos | 20 | 2012-01-01 | 2012-01-27 |
| A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product. Marine active - "Hyperuricemia,Anserine" | Phase 2 | Unknown | China Medical University Hospital | 2004-07-01 | 2010-11-29 |
Gout (2) · Heart Failure (1)
Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Arthritis (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Crystal Arthropathies (2) · Genetic Diseases, Inborn (2) · Joint Diseases (2) · Metabolic Diseases (2) · Metabolism, Inborn Errors (2) · Musculoskeletal Diseases (2) · Nutritional and Metabolic Diseases (2) · Purine-Pyrimidine Metabolism, Inborn Errors (2) · Rheumatic Diseases (2) · Cardiovascular Diseases (1) · Heart Diseases (1)
Febuxostat (2) · Prednisone (1) · ruzinurad (1) · tofisopam (1)
Jiangsu HengRui Medicine Co., Ltd. (2) · China Medical University Hospital (1) · Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd (1) · Hebei Medical University (1) · Pharmos (1)
China (2) · Taiwan (1) · United States (1)
Chiu-Shong Liu, Director (1) · John S. Sundy, MD, PhD (1) · Liu Yi (1)